MyFinsight
Home
Blog
About
Contact
Download
Download image
Cash and cash
equivalents
$3,008,500K
(26.67%↑ Y/Y)
Inventory
$2,168,100K
(-11.88%↓ Y/Y)
Accounts receivable, net
of allowance for...
$1,342,400K
(-4.44%↓ Y/Y)
Other current assets
$1,123,300K
(49.28%↑ Y/Y)
Current portion of
marketable securities
$807,200K
Due from anti-cd20
therapeutic programs
$524,600K
(13.06%↑ Y/Y)
Intangible assets, net
$9,178,500K
(-5.29%↓ Y/Y)
Total current assets
$8,974,100K
(20.35%↑ Y/Y)
Goodwill
$6,491,100K
(0.19%↑ Y/Y)
Property, plant and
equipment, net
$3,055,400K
(-3.96%↓ Y/Y)
Investments and other assets
$750,600K
(33.92%↑ Y/Y)
Marketable securities
$431,900K
Deferred tax asset
$292,500K
(-9.78%↓ Y/Y)
Operating lease assets
$265,400K
(-25.53%↓ Y/Y)
Total assets
$29,439,500K
(4.96%↑ Y/Y)
Total liabilities and
equity
$29,439,500K
(4.96%↑ Y/Y)
Total equity
$18,256,800K
(9.22%↑ Y/Y)
Total liabilities
$11,182,700K
(-1.33%↓ Y/Y)
Treasury stock, at cost
23.8 million and 23.8...
$2,977,100K
(0.00%↑ Y/Y)
Accumulated other
comprehensive income (loss)
-$182,000K
(-33.63%↓ Y/Y)
Retained earnings
$20,552,700K
(6.71%↑ Y/Y)
Notes payable
$6,286,800K
(38.26%↑ Y/Y)
Total current
liabilities
$3,349,400K
(-39.42%↓ Y/Y)
Other long-term
liabilities
$748,500K
(2.21%↑ Y/Y)
Deferred tax liability
$507,600K
(166.46%↑ Y/Y)
Long-term operating lease
liabilities
$290,400K
(-13.18%↓ Y/Y)
Additional paid-in capital
$863,100K
(51.58%↑ Y/Y)
Common stock, par value
0.0005 per share
$100K
(0.00%↑ Y/Y)
Accrued expense and
other
$2,802,600K
(-0.18%↓ Y/Y)
Accounts payable
$432,000K
(1.84%↑ Y/Y)
Taxes payable
$114,800K
(-79.06%↓ Y/Y)
Back
Back
Balance Sheet
source: myfinsight.com
Biogen-svg
BIOGEN INC. (BIIB)
Biogen-svg
BIOGEN INC. (BIIB)